A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome (RUBENS Trial)

This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as monotherapy, on top of guideline-recommended lipid-lowering therapy in patients with metabolic syndrome and/or Type 2 Diabetes Mellitus.

Start Date11 Dec 2025

Sponsor / Collaborator

NewAmsterdam Pharma Corp.

NCT06982508

/ RecruitingPhase 2

A Randomized, Double-Blind, Placebo-Controlled Parallel Trial to Assess the Effects of Obicetrapib on Levels of Antioxidants in Plasma and HDL Particles in Healthy Volunteers: The VERMEER Study

The goal of this clinical trial is to learn if Obicetrapib works to change antioxidant levels in HDL and plasma, as well as retinal tissue. The main questions it aims to answer are:
Do Obicetrapib effect absorption of antioxidants in a person's blood or their eye tissue? Researchers will compare Obicetrapib to a placebo (a look-alike substance that contains no drug) to see if Obicetrapib helps improve a person's ability to absorb antioxidants.
Participants will:
Take Obicetrapib or a placebo every day for 4 months Visit the clinic once every 8 weeks for checkups and tests Have their blood taken and their eyes checked to measure antioxidant levels

Start Date09 Sep 2025

Sponsor / Collaborator

MB Clinical Research & Consulting LLC

NCT06496243

/ RecruitingPhase 2

A Phase 2 Study to Evaluate the Effect of Obicetrapib Alone and in Combination With Evolocumab (Repatha®) on Lipoprotein (a) in Patients With Mild Dyslipidemia: The VINCENT Study

The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab
Patients will:
Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg/dL obicetrapib daily/evolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16

Start Date02 Dec 2024

Sponsor / Collaborator

NewAmsterdam Pharma Co. NV

100 Clinical Results associated with Obicetrapib

100 Translational Medicine associated with Obicetrapib

100 Patents (Medical) associated with Obicetrapib

Literatures (Medical) associated with Obicetrapib

01 Jul 2026·Medicina de Familia-SEMERGEN

Systematic review and meta-analysis on the safety and efficacy of obicetrapib combination therapy in dyslipidemia

Article

Author: Rab Nawaz, S ; Ibrahim Smeak, R ; Hammad Arif, M ; Andleeb, B ; Nawaz, M ; Waheed, N ; Timsina, G ; Hassan Zafar, M ; Ahmad, B ; Ahmad Khan, U

AIM:

To evaluate the efficacy of obicetrapib combination therapy group against the obicetrapib alone or placebo arm.

BACKGROUND:

Recently, the drug obicetrapib has been explored as a combination therapy with other lipid-lowering therapies as a treatment option for dyslipidemia, with the potential to affect atherogenic lipoproteins.

METHODS:

This review registered with PROSPERO (CRD420251112605) included adult patients with LDL-C levels greater than 70mg/dl. A comprehensive search strategy was developed on PubMed, Cochrane Central and ClinicalTrials.gov to identify randomized controlled trial (RCT's). For risk of bias assessment, ROB 2.0 tool was used. The mean difference (MD) and risk ratio (RR) were calculated via a random effects model using RStudio version 4.5.1.

RESULTS:

We identified six RCT's with a total of 657 patients. LDL-C, Apo-B, and non-HDL-C were notably reduced in the obicetrapib combination therapy group, with MDs of -44.14 (95% CI: -54.83, -33.45), -28.94 (95% CI: -37.50, -20.38), and -35.45 (95% CI: -48.46, -22.45), respectively. Moreover, HDL-C levels were improved in the combination therapy group, with an MD of 149.15 (95% CI: 136.88, 161.42). The incidence of adverse outcomes was reported to be insignificant.

CONCLUSION:

Our analysis revealed greater reductions in the levels of atherogenic lipoproteins, with obicetrapib combination therapies compared to placebo arm and obicetrapib monotherapy. A higher obicetrapib dosage (10mg), and combination with ezetimibe resulted in more reductions in lipoprotein levels. Although there is possibility for the effectiveness of obicetrapib combination therapies however due to high heterogeneity results needed to be interpreted with caution.

01 Jun 2026·CARDIOVASCULAR DRUGS AND THERAPY

Lipoprotein(a) in Cardiovascular Diseases and Emerging Therapeutic Strategies

Review

Author: Smith, Emily Lauren Schenk ; Selico-Dunn, Alexandra C ; Al-Horani, Rami A

Abstract:

Purpose:

Lipoprotein(a) [Lp(a)] is increasingly recognized as a genetically determined, independent risk factor for atherosclerotic cardiovascular disease (ASCVD). This review examines the structure, pathophysiology, and epidemiology of Lp(a), with a focus on its contribution to ASCVD and related conditions such as aortic valve stenosis and peripheral artery disease. The main research question addresses how Lp(a) influences cardiovascular risk and how emerging therapies may modify this risk.

Methods:

This review synthesizes published evidence describing the biological characteristics of Lp(a), its mechanistic roles in disease, and its epidemiologic associations with cardiovascular outcomes. It also evaluates current and investigational therapeutic approaches by examining clinical trial data for agents targeting Lp(a).

Results:

Lp(a) contributes to residual cardiovascular risk through proatherogenic, proinflammatory, and prothrombotic mechanisms. Current evidence highlights its involvement in ASCVD, aortic valve stenosis, and peripheral artery disease. Clinical studies of antisense oligonucleotides, small interfering RNAs, oral small molecules, and CRISPR-based gene editing, including pelacarsen, olpasiran, zerlasiran, lepodisiran, muvalaplin, and obicetrapib, demonstrate promising efficacy and safety. These agents show potential to significantly reduce Lp(a) levels and influence future cardiovascular prevention strategies.

Conclusion:

As novel therapies advance and clinical guidelines evolve, Lp(a) is emerging as a central determinant in personalized cardiovascular care. The increasing emphasis on Lp(a) testing underscores its importance in risk stratification and future therapeutic decisionmaking.

01 Jun 2026·Vascular diseases (Paris, France)

Lipid-modifying efficacy and safety of obicetrapib in high-risk cardiovascular patients: A systematic review and meta-analysis

Review

Author: Lemus-Zamora, Ricky E ; Kayani, Abdul Mueez Alam ; Garcia, Alan ; Umar, Muhammad Faiq ; Navarro-Martinez, Daniel ; Rashid, Muhammad Affan

INTRODUCTION:

Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality, particularly among high-risk patients. Despite the availability of multiple lipid lowering therapies, many patients fail to achieve the guideline recommended low-density lipoprotein cholesterol (LDL-C) targets. Obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor optimizes lipid profile by blocking the exchange of cholesterol esters from high-density lipoprotein cholesterol (HDL-C) to Apolipoprotein B (ApoB) containing lipoproteins. This study evaluates the efficacy and safety of obicetrapib as an adjunctive therapy in high-risk ASCVD patients.

METHODS:

Online databases were searched. Outcomes included percentage changes in LDL-C, HDL-C, non-HDL-C, total cholesterol, triglyceride, ApoB, lipoprotein (a) [Lp(a)] and risk of any adverse events (AE), AE leading to discontinuation, acute kidney injury (AKI), transaminase or creatine kinase (CK) elevation and hypertension. Risk ratio (RR) for categorical outcomes and mean difference (MD) for continuous outcomes were reported using 95% confidence intervals (CI).

RESULTS:

Three studies with 3088 patients (mean age 64 ± 11, 37% female) were selected. Obicetrapib significantly reduced LDL-C (-31.75%), non-HDL-C (-29.35%), triglyceride (-5.61%), Lp(a) (-35.67%), ApoB (-19.37%), and increased HDL-C (+125.94%) with no difference in total cholesterol levels. Obicetrapib was not associated with increased risk for any AE, AE leading to discontinuation, AKI, transaminase or CK elevation, and hypertension.

CONCLUSION:

Obicetrapib substantially improved lipid profiles in high-risk ASCVD patients on maximally tolerated lipid lowering therapy, without increased short-term adverse events. However, further long-term randomized studies are needed to confirm sustained efficacy, long-term safety, and potential impacts on clinical cardiovascular outcomes.

135

News (Medical) associated with Obicetrapib

07 Jul 2026

·www.prnewswire.com

Cambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in Pharma

EAST RUTHERFORD, N.J., July 7, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), proudly announces that Snapdragon Chemistry, a Cambrex company, together with NewAmsterdam Pharma, has received the American Chemical Society's 2026 Green Chemistry Challenge Award for the Greener Synthetic Pathway in the Synthesis of Pharmaceuticals. The award recognizes the companies' successful development of a sustainable organocatalytic process to manufacture the chiral tetrahydroquinoline core for the synthesis of obicetrapib, a late-stage investigational therapy for dyslipidemia. NewAmsterdam Pharma, in collaboration with Snapdragon Chemistry, developed an industrial-scale synthesis of an organocatalyzed asymmetric Povarov cyclization to manufacture the chiral tetrahydroquinoline core, a key intermediate in the synthesis of obicetrapib. Compared with the previous manufacturing route, the organocatalytic process significantly improved overall efficiency and sustainability, delivering substantial gains in yield, reducing process mass intensity by approximately 80%, eliminating aqueous waste generation, shortening manufacturing cycle time by approximately 70% and lowering manufacturing costs by approximately 50%. Furthering its sustainability leadership, Cambrex's Milan facility has been awarded the EcoVadis Gold rating, placing it among the top 5% of organizations evaluated for environmental, social and ethical performance. This distinction reflects Cambrex's comprehensive sustainability strategy, including a 20% reduction in greenhouse gas emissions network-wide and a goal to reduce emissions by 50% by 2030. Additionally, Q1 Scientific, a Cambrex company, has partnered with Flogas through a Corporate Power Purchase Agreement (CPPA) to source renewable electricity from the Cronalaght Wind Farm. This partnership will cover approximately 50% of the Q1 Scientific Waterford site's electricity demand, supporting both client and community environmental goals and reinforcing Cambrex's position as a responsible industry leader. Thomas Loewald, CEO at Cambrex commented, "At Cambrex, we are dedicated to continually reducing our environmental impact for the benefit of our communities and ensuring long-term, sustainable manufacturing solutions for our customers." About Cambrex Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical services. With over 45 years of experience and a team of 2,000 experts servicing global clients from North America and Europe, Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, peptide synthesis, solid-state science, biocatalysis, material characterization, complex synthetics, and highly potent APIs. Logo - 21% more press release views with Request a Demo

02 Jul 2026

·www.biospace.com

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 2, 2026

NAARDEN, The Netherlands and MIAMI, July 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 28,700 of NewAmsterdam’s ordinary shares to four non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price per share equal to $35.17, which represents the closing market price on the Nasdaq Stock Market of the Company’s ordinary shares on July 1, 2026, the grant date. The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 equal monthly installments thereafter, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The options are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant. The Compensation Committee of NewAmsterdam’s Board of Directors also approved the grant of restricted stock units covering an aggregate of 8,100 of NewAmsterdam’s ordinary shares to four non-executive new hires. The restricted stock units were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units were granted on July 1, 2026. The restricted stock units will vest over three years, with one-third of the restricted stock units vesting on each of the one-year, two-year and three-year anniversaries of the applicable vesting commencement date, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The restricted stock units are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of a restricted stock unit award agreement covering the grant. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company Contact Matthew Philippe P: 1-917-882-7512 matthew.philippe@newamsterdampharma.com

Phase 3AHA

01 Jul 2026

·www.biospace.com

NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer’s Association International Conference (AAIC) 2026

NAARDEN, the Netherlands and MIAMI, July 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for the prevention of early Alzheimer’s disease, at the Alzheimer's Association International Conference (AAIC) 2026, taking place on July 12 – 15, 2026 in London, United Kingdom. Presentation details are as follows: Title: Predictors of P-tau217 in Cardiovascular Patients: Insights from the Broadway Trial Abstract ID Number: 2026-A-6102-AAIC Session Title: 2-17-FRS-A Featured Research Sessions: Alzheimer’s Therapy: Mechanisms Beyond Amyloid Oral Presentation Date and Time: Monday, July 13, 2026 at 9:30 AM BST Location: George V 1/2 Title: Undiagnosed Alzheimer’s Pathology in Cardiovascular Patients and its Implications for Prevention: BROADWAY Trial Dissected Abstract ID Number: 2026-A-5998-AAIC Poster Number: 0057 Session Title: In-Person Posters: Drug Development Poster Presentation Date and Time: Tuesday, July 14, 2026 at 7:30 AM – 4:30 PM BST Location: ICC Maritime Hall Title: ApoE4-Dependent Dose Response to CETP Inhibition: A Responder Analysis Informing Alzheimer’s Prevention Trial Enrichment Strategies Abstract ID Number: 2026-A-8875-AAIC Poster Number: 0435 Session Title: In-Person Posters: Biomarkers: Biomarkers (non-neuroimaging) Poster Presentation Date and Time: Tuesday, July 14, 2026 at 7:30 AM – 4:30 PM BST Location: ICC Maritime Hall Title: CETP Inhibition for Alzheimer’s Prevention: Obicetrapib’s Multi-Pathway Effects on Lipid Mediated Pathophysiology Abstract ID Number: 2026-A-5685-AAIC Poster Number: 0056 Session Title: In-Person Posters: Human Drug Development Poster Presentation Date and Time: Wednesday, July 15, 2026 at 7:30 AM – 4:30 PM BST Location: ICC Maritime Hall About Obicetrapib Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect pro to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. Alzheimer’s Analysis In BROADWAY, a pre-specified analysis was designed to assess plasma biomarkers of Alzheimer’s disease (“AD”) in patients enrolled in the BROADWAY trial and evaluated the effects of longer duration of therapy (12 months) with a prespecified ApoE population, based on phenotypic analysis. The analysis included 1,535 patients, including 367 ApoE4 carriers (ApoE3/E4 or ApoE4/E4), whose ApoE status was able to be determined. Because this analysis was based on a subset of patients from BROADWAY (which was designed to evaluate LDL-C reductions in an ASCVD and/or HeFH population), the AD analysis was not controlled for baseline differences between the treatment and placebo populations, but statistical analyses were adjusted for baseline biomarker values and age. The absolute and percent change over 12 months in p-tau217, a key biomarker of AD pathology, was measured among patients with baseline and end of study datapoints above the lower limit of quantitation. Additional outcome measures included NFL, GFAP, p-tau181, and Aβ42/40 ratio absolute and percent change over 12 months. NewAmsterdam observed statistically significant lower absolute changes in p-tau217 compared to placebo over 12 months in both the full analysis set (p=0.025; n= 1,535) and in ApoE4 carriers (p=0.022; n=367) as well as favorable trends in the other AD biomarkers. Although a safety analysis was not performed in the AD analysis population, in BROADWAY obicetrapib was observed to be well-tolerated, with safety results comparable to placebo. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company Contact Matthew Philippe P: 1-917-882-7512 matthew.philippe@newamsterdampharma.com Media Contact Real Chemistry on behalf of NewAmsterdam Christian Edgington P: 1-513-310-6410 cedgington@realchemistry.com Investor Contact Precision AQ on behalf of NewAmsterdam Austin Murtagh P: 1-212-698-8696 austin.murtagh@precisionaq.com

Clinical ResultPhase 3Phase 2

100 Deals associated with Obicetrapib

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14890

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Primary hypercholesterolemia	NDA/BLA	European Union	NewAmsterdam Pharma Co. NV	18 Aug 2025
Diabetes Mellitus, Type 2	Phase 3	United States	NewAmsterdam Pharma Corp.	11 Dec 2025
Hyperlipidemias	Phase 3	United States	NewAmsterdam Pharma Corp.	11 Dec 2025
Metabolic Syndrome	Phase 3	United States	NewAmsterdam Pharma Corp.	11 Dec 2025
Hyperlipoproteinemias	Phase 3	United States	NewAmsterdam Pharma Holding BV	25 Jul 2022
Hyperlipoproteinemias	Phase 3	Canada	NewAmsterdam Pharma Holding BV	25 Jul 2022
Hyperlipoproteinemias	Phase 3	Czechia	NewAmsterdam Pharma Holding BV	25 Jul 2022
Hyperlipoproteinemias	Phase 3	Netherlands	NewAmsterdam Pharma Holding BV	25 Jul 2022
Hyperlipoproteinemias	Phase 3	Norway	NewAmsterdam Pharma Holding BV	25 Jul 2022
Hyperlipoproteinemias	Phase 3	Poland	NewAmsterdam Pharma Holding BV	25 Jul 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05425745 (BROOKLYN, Pubmed \| Nat Med)	Phase 3	Heterozygous familial hypercholesterolemia	354	Obicetrapib 10 mg	pteetasecp(bivnpzmxhr): Difference (%) = -36.3 (95.0% CI, -42.2 to -30.4), P-Value = < 0.0001	Positive	27 Feb 2026
				Placebo
NCT06005597 (TANDEM, CTgov)	Phase 3	Atherosclerosis \| Heterozygous familial hypercholesterolemia	407	Ezetimibe Placebo (Placebo)	qcdwhmyqqb(ulqbnqrfgr) = sgapytynpy qbcunyiztp (hlvnxovbfy, 3.564) View more	-	08 Oct 2025
				Combination Therapy placebo+Monotherapy ezetimibe (Monotherapy Ezetimibe)	edabtlsqac(dppexdwzqt) = wvduwvnsip kswworlydj (zxromqeuyi, 3.497) View more
NCT05142722 (BROADWAY, Pubmed \| J Prev Alzheimers Dis)	Phase 3	Cardiovascular Diseases p-tau217 \| p-tau217/Aβ42:40 \| GFAP ... View more	1,535	Obicetrapib 10 mg	avncerhrnj(oeftgqwccs) = mltdtdflor ackkiglgvv (kivempjtjh ) View more	Positive	01 Oct 2025
				Placebo	avncerhrnj(oeftgqwccs) = gqoerpplfj ackkiglgvv (kivempjtjh ) View more
NCT05142722 (BROADWAY, CTgov)	Phase 3	Atherosclerosis \| Heterozygous familial hypercholesterolemia	2,530	Placebo (Placebo)	femaqbugyr(xwvwaiieht) = ondrlyrmat pzozxplxcb (zggizbavkg, 1.571) View more	-	19 Sep 2025
				Obicetrapib (Obicetrapib 10mg)	femaqbugyr(xwvwaiieht) = oxzkkomwed pzozxplxcb (zggizbavkg, 1.104) View more
NCT05142722 \| NCT05425745 (BROADWAY, Literature) Manual	Not Applicable	Heterozygous familial hypercholesterolemia \| Atherosclerosis	2,884	Obicetrapib 10 mg	vfykhmxjpd(xmthljvphx) = jsozlmpgjf lfoluetkdz (hajvnpkkku ) View more	Positive	01 Sep 2025
				Placebo	vfykhmxjpd(xmthljvphx) = xofynklrpt lfoluetkdz (hajvnpkkku ) View more
NCT05142722 (BROADWAY, GlobeNewswire) Manual	Phase 3	Heterozygous familial hypercholesterolemia \| Atherosclerosis	1,515	Obicetrapib 10 mg	elclbxxukk(zswccbmnfa): Difference (%) = -20.48, P-Value = 0.010 View more	Positive	30 Jul 2025
				Placebo
NCT05142722 (BROADWAY, Pubmed \| N Engl J Med \| NEWS) Manual	Phase 3	Heterozygous familial hypercholesterolemia \| Atherosclerosis	2,530	ObicetrapibObicetrapib 10 mg	veoxzgdznq(xyadmsqvwu) = iqnnhmicxj vzglhgovph (ripzijgfqe, -32.1 to -27.8)	Positive	03 Jul 2025
				Placebo	veoxzgdznq(xyadmsqvwu) = inwgwhiimm vzglhgovph (ripzijgfqe, -0.4 to 5.8)
NCT05425745 (BROOKLYN, CTgov)	Phase 3	Hyperlipoproteinemias \| Heterozygous familial hypercholesterolemia	354	Placebo (Placebo)	urubpbgerw(qbhjipcbvv) = qrplzzclqi dbwxmtrrch (eunbvhxtlz, 2.480) View more	-	11 Jun 2025
				Obicetrapib (Obicetrapib 10 mg)	urubpbgerw(qbhjipcbvv) = oohleonzcg dbwxmtrrch (eunbvhxtlz, 1.769) View more
NCT05142722 (BROADWAY, GlobeNewswire) Manual	Phase 3	Heterozygous familial hypercholesterolemia \| Atherosclerosis	-	Obicetrapib 10 mg	xugratcntc(ntaqljvekf) = yrnahpippu lesegoyuqh (qrlsbbynoy ) View more	Positive	10 Dec 2024
				Placebo	xugratcntc(ntaqljvekf) = obdkzogdkm lesegoyuqh (qrlsbbynoy ) View more
NCT06005597 (TANDEM, Company_Website) Manual	Phase 3	Heterozygous familial hypercholesterolemia \| Atherosclerosis	407	Placebo	mekppbjnbd(zmibriblmi) = sjqdqtfwyk qmzcekemnw (owpqxdeawp ) View more	Positive	20 Nov 2024
				Ezetimibe	mekppbjnbd(zmibriblmi) = zoqhwekxkp qmzcekemnw (owpqxdeawp ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis